BioSpace News Archive

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced that it has priced its underwritten public offering.

Sequana Medical NV announces the successful completion of its GLP animal studies, demonstrating the safety of its second-generation DSR product, following chronic exposure.

Biovica International Biovica, active in cancer monitoring, announces that the company’s test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market.

Gerresheimer AG announced a joint venture with Corning Incorporated, a leading innovator in materials science and manufacturing, to increase global access to the Velocity® Vial technology platform, addressing the need for a high-quality and cost-effective injectable drug filling process.

Enzolytics, Inc. announced today the preliminary results of Toxicology studies of the Company’s ITV-1 anti-HIV therapeutic confirming that the therapy is non-toxic and demonstrating the safety of administration of this patented proprietary immunotherapy.

Pierre Fabre and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre.

West Pharmaceutical Services, Inc. announces the expansion of its landmark collaboration with Corning Incorporated, that now includes the exclusive distribution rights for Corning Valor® Glass vials and the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials utilizing SG EZ-fill® technology.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2022 financial results on Thursday, February 23, 2023, after the market close.

The Preeclampsia Foundation announced today the recipient of its 2023 Peter Joseph Pappas Research Grants at the Society for Maternal Fetal Medicine 43rd Annual Pregnancy Meeting. Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.